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 Endothelial cells inhibit platelet aggregation by releasing thromboregulators, 
such as prostacyclin and nitric oxide. Male subject is a traditional risk factor 
for cardiovascular diseases. Platelet hyperreactivity has been frequently 
found in patient with diabetes mellitus. To examine whether testosterone and 
high glucose modify platelet aggregation through endothelial cells, we did an 
in vitro study using endothelial cells culture from human umbilical vein 
(HUVEC). Treatments were performed in HUVEC sub culture as either 
normoglucose (5.6 mM) or high glucose (22.4 mM) medium, with or without 
testosterone (0, 1, 10, 100 nM), for 24 hours. HUVEC were trypsinized, 
resuspended, and then incubated with platelet rich plasma from healthy male 
donors with ratio 1:104 for 3 minutes. Platelet aggregation measured by 
turbidimetry methode. This study showed that testosterone did not 
significantly influence platelet aggregation through endothelial cells in 
normoglucose (p = 0.144) or high glucose (p = 0.916) medium. There was no 
main effect of testosterone (p = 0.73) as well as no interaction between 
testosterone and glucose (p = 0.69), but there was a main effect of glucose (p 
= 0.004), to platelet aggregation through endothelial cells. In conclusion, 
high glucose, but not testosterone, inhibits platelet aggregation mediated by 
endothelial cells. 
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1. INTRODUCTION  
Endothelial cells (EC) form continues monolayer epithelial cells lining the internal lumen of the 
blood vessels. In normal physiological condition, EC, being exposed to blood glucose levels in range 3.6-5.8 
mmol/L, is characterized as antithrombotic and anticoagulant. However, when EC are being exposed to 
hyperglycemia, as the hallmark of diabetes mellitus (DM), cell homeostasis is perturbed and EC may change 
to be prothrombotic and procoagulant. Endothelial dysfunction is believed to occur before the development 
of microvascular and macrovascular complications in type 2 diabetes mellitus (T2DM) patients. The 
underlying mechanism includes the accelerated formation of advanced glycation end product and activation 
of protein kinase C [1]-[2].  
In recent years, testosterone (T) gets more attention as a potential player in cardiovascular diseases 
(CVD), although male sex has been recognized as a traditional risk factor in CVD for a long time ago. 
Androgen receptor (AR) and enzymes that metabolizes T are found in EC and the rest of cardiovascular (CV) 
system [3]-[4]. T may affect EC by genomic and non-genomic pathway. However, the results of the studies 
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in this area are still conflicting. For example, as the level of serum T is rather low in patients with CVD, as 
well as in aging men, T replacement offers a potential benefit but abrupt uprising of T level, such as 
experienced by athletes who take androgen, is associated with CV events [5]-[7].  
In CV events, platelet aggregation can be regarded as the early event that will lead to thrombosis 
formation [8]. Fortunately, EC will response to platelet activation by releasing thromboregulators, such as 
prostacyclin and nitric oxide [9]. Thus, it is very interesting to examine whether the capacity of EC was 
changed after exposure of T in normoglucose (NG) or high glucose (HG) environment. 
 
 
2. RESEARCH METHOD  
The study was approved by the Institutional Review Board of the Faculty of Medicine Gadjah Mada 
University (FM GMU), Yogyakarta. Donors for umbilical cords (n = 2) were mothers who delivered her 
baby in a midwifery clinic or Muhammadiyah’s hospitals in Yogyakarta. The mothers had no hypertension, 
diabetes mellitus, and (pre) ecclampsia, the delivery was aterm, and the baby was having Apgar score >10. 
Donors for platelets (n = 2) were healthy male subjects from FM GMU, who were 30-40 years old, had body 
mass index <28 kg2/m2, platelets count >100,000/mm3, O blood type, normal platelet aggregation, and with 
no DM, hypertension, and history of blood disorders. All participants were capable of giving informed 
consent. 
 
2.1. Endothelial cells culture  
Medium 199 (M199) was using as culture medium that was prepared from the powdered M199 
(Gibco) added with 2 g of sodium bicarbonate and 2 g of HEPES sodium salts. Growth medium was M199 
supplemented with 10% fetal bovine serum (FBS) (Caisson), 100 IU/mL of penicillin and 100 µg/mL of 
streptomycin (Sigma), 0.5% fungizone (Gibco), and 2 mM of L-glutamine (Sigma).  
The umbilical cord buffer was prepared from 9.6 g of Dulbecco’s phosphate buffered saline (PBS) 
powder that dissolved with distilled water into 1000 mL in total volume. The solution was put into glass 
bottles and sterilized with autoclave at 1210C, for 15 minutes. After sterilizing, add 100 IU/mL of penicillin 
and 100 µg/mL of streptomycin, that obtained from crystalline procaine penicillin-G powder (Meiji) and 
streptomycin sulfate powder (Meiji) dissolved with sterilized water for injection. This buffer solution was 
kept at 40C.  
Human umbilical vein endothelial cells (HUVEC) culture was established according to the 
technique describes by Jaffe et al. [10], Tanaka (School of Medicine, Kobe University) [11], and Baudin et 
al. [12] The umbilical cord taken from donors was placed in sterile bottle contained buffer solution (PBS-1% 
Pen Strep) at 40C until processed in the laboratory within 24 hours of collection. After the outside of the 
umbilical cord was cleaned with povidone iodine, the lumen of umbilical vein was identified. Cannula needle 
was inserted into the vein and kept tightly with a clamp. Then the umbilical vein was flushed with ringer 
lactate solution until it was free from remaining blood. The next step was filling the umbilical vein with 
enzyme solution to disaggregate EC. For that, warm 0.25% trypsin-EDTA (Gibco) was injected into the vein 
until it was distended. Another open end of the cord was clamped. The umbilical cord was incubated for 2 
minutes into a beaker glass filled with warm PBS. After incubation period, the clamp was taken off and the 
enzyme solution was collected into a sterile bottle already filled with 1 cc of FBS. The effluent was replaced 
into a conical tube to be centrifuged at 2000 rpm for 10 minutes. The supernatant was removed and the pellet 
was washed once with M199. Then the cell was resuspended with growth medium and inoculated on a 
gelatine-coated 60 mm-diameter tissue culture dish (Iwaki). The dish was incubated at 370C and 5% CO2 for 
24 hours. On the following day, the growth medium was changed after the dish was washed with PBS-1% 
Pen Strep to remove red blood cells. The growth medium was changed every 2 days until it reached 80% 
confluence. The cells were observed under an inverted microscope (Eclipse, Nikon, Japan).  
HUVEC passage 2 were growth on gelatin-coated coverslip after reaching confluence were 
characterized by the presence of von-Willebrand factor (vWF) [13]-[14]. Immunocytochemistry was done for 
cell characterization. Monolayer HUVEC on gelatin-coated coverslip was fixed with methanol. Anti-vWF 
rabbit polyclonal antibody (1:50; Novocastra, Newcastle, UK) was used as the primary antibody for 1 h at 
RT, followed by trekie universal link (Starr Trek, Biocare Medical, Netherlands) as the secondary antibody 
for 20 minutes at RT. The coverslips were incubated with TrekAvidin horse raddish peroxidase (HRP) label 
(Starr Trek) for 10 minutes, and followed by betazoid 3-3’ diaminobenzidin (DAB) chromogen (1:50; Starr 
Trek) for 2 minutes. The coverslip was counterstained with Mayer’s hematoxylin (Merck, Darmstadt, 
Germany) for 2 minutes, and then underwent dehydration series using ethanol and xylol. The coverslip was 
finally mounted on a microscope glass using xylene-based mounting medium (EZ-Mount, Shandon, Thermo 
Scientific, USA). The cells were examined under an optic microscope (Olympus, Japan).  
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2.2. Platelet rich plasma  
Venous blood was collected into 1/10 volume of 3.8% sodium citrate from the donors. The whole 
blood was centrifuged at 900 rpm for 15 minutes. The supernatant i.e. platelet rich plasma (PRP) was 
collected. The remaining blood was centrifuged at 1500 rpm for another 15 minutes to get platelet poor 
plasma (PPP). The PRP and PPP were kept at room temperature until platelet aggregation test was performed 
within 3 hours.  
 
2.3. Treatment 
Primary HUVEC reached 80% confluenceon the 6-9th day. The HUVEC monolayer was trypsinized 
with 0.25% trypsin-EDTA and counted. The EC were plated in a gelatin-coated 24-well microplate (Iwaki) at 
2x104cells/well. After 24 hours the growth medium of the secondary HUVEC was replaced with either NG 
(5.6 nM) or HG M199 growth medium (22.4nM) without or with T at 0, 1, 10, or 100 nM. For the next 24 
hours, the treatment was removed and the monolayer EC were washed with PBS, trypsinized with 0.25% 
trypsin-EDTA, centrifuged at 2000 rpm for 5 minutes, and resuspended with 500 µL of serum free M199.  
 
2.4. Platelet aggregation test 
Platelet aggregation test was done with turbidimetric methode using an aggregometer machine and 
adenosine diphosphate (ADP) as platelet agonist, both were from Helena Laboratory. 5 µM of ADP was 
prepared by diluting 20 µM of ADP with 0.9% of saline with ratio 1:3. Light transmittance measurement was 
taken to the following: an empty cuvette, a cuvette filled with 300 µL of aquadest, and a cuvette filled with 
450 µL of PPP. Another 4 cuvettes were prepared with a magnetic strirrer inside. 50 µL of endothelial cell 
suspension was put into each cuvette, according to the designated treatment group.  50 µL of PRP was added 
into the cuvette to reach ratio 104:1 to the EC and incubated for 3 minutes at 370C. Finally, 50 µL of 5 µM 
ADP was added into the cuvette, and the reading of light transmittance for platelet aggregation was started. 
During 10 minutes-reading, variabels such as Max%, TMax, slope, lag and % area under curve were 
recorded. To examine the treatment effect, Max% or maximal platelet aggregation in percentage was used as 
the parameter.  
 
2.5. Statistic analysis  
One way ANOVA was used to analyse the influence of T at various doses in either NG or HG 
medium. Analysis of varians was used to analyse 2x4 factorial designs. p value <0.05 was considered 
significant. 
 
 
3. RESULTS AND ANALYSIS  
 
3.1. Endothelial cells culture  
Primary EC culture was established from human umbilical vein (human umbilical vein endothelial 
cells; HUVEC) using enzymatic digestion. The endothelial cell culture reached confluence at 6-9th day. EC 
culture was identified by morphological and immunological approach. By morphological identification using 
a phase contrast microscope, EC were observed as mononucleate and polygonal epithelial cells. A confluent 
monolayer of EC showed cobblestone appearance as shown in Figure 1.  
 
 
 
 
Figure 1. The morphology of a confluent monolayer of endothelial cells 
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Endothelial cells were growth in complete medium as described in the Research Method. Cells were 
reached confluent after 6 days and showed the cobblestone appearance of closely packed mononucleate and 
polygonal endothelial cells. Cells were observed under inverted microscope with 100x maginification. 
By immunological identification using immunocytochemistry method, the EC culture positively 
expressed von Willebrand factor (vWF) at the cell membrane as shown in Figure 2. 
 
 
 
 
Figure 2. The positive expression of von Willebrand factor (vWF) in endothelial cells 
 
 
Endothelial cells from human umbilical vein (HUVEC) passage 2 were growth on a gelatin-coated 
coverslip. A confluent monolayer EC was fixed and immunolabelled with anti-vWF polyclonal antibody as 
described in the Research Method. The vWF expression was detected on the cell membrane (brown). 
Mayer’s hematoxylin was used to counterstain the nuclei (purple). Cells were observed under inverted 
microscope with 40x magnification. 
 
3.2. Platelet aggregation test 
By using luminisence turbidimetric method, maximal platelet aggregation was measured in PRP 
after incubated with EC previously treated with testosterone in NG or HG medium. The results are presented 
in Table 1.   
 
 
Table 1. Maximal platelet aggregation mediated by endothelial cells treated with testosterone and glucose  
Testosterone level in the 
EC culture medium 
(nM) 
Percentage of maximal platelet aggregation mediated by endothelial cells 
from two different glucose content in the culture medium 
Normoglucose High glucose 
0 29.3 ± 5.8 46.5 ± 10.7 
1 25.0 ± 6.8 43.9 ± 1.4 
10 
100 
28.5 ± 7.0 
29.1 ± 9.9 
48.1 ± 0 
37.4 ± 2.3 
Note. Maximal platelet aggregation is presented as mean ± SD from 2 independent experiments. EC 
= endothelial cells. Normoglucose = 5.6 mM glucose in the EC culture medium. High glucose = 
22.4 mM glucose in the EC culture medium.  
 
 
As seen in the Table 1, percentage of maximal platelet aggregation of PRP after incubated with EC 
previously treated with NG medium was lower than of PRP after incubated with EC previously treated with 
HG medium, in each level of T in the culture medium. By one-way ANOVA analysis, exposure of T at 
various doses to EC did not show significant influences to maximal platelet aggregation in either NG (p = 
0.144) or HG medium (p = 0.916). By analysis of varians for 2x4 factorial design, there was a main effect of 
glucose to EC to maximal platelet aggregation (p = 0.004). However, there was no main effect of T to EC to 
maximal platelet aggregation (p = 0.073). Moreover, there was no interaction between T and glucose to EC to 
maximal platelet aggregation (p = 0.69).  
The aim of this study is to investigate the influence of T and HG condition to the normal function of 
EC in preventing platelet aggregation. This in vitro experiment is specific to examine the influence of T and 
HG to EC in relation to the early stage of thrombosis. However, this model is not compatible with real 
condition, in which hyperglycemia or T or the combination condition will affect EC and platelets at the same 
time.  
IJPHS ISSN: 2252-8806  
 
High Glucose, but Not Testosterone, Increases Platelet Aggregation Mediated  .... (Ikhlas Muhammad Jenie) 
209
Rosenblum et al. [15] had investigated the influence of T to platelet aggregation by implanting 
subcutaneously T or dihydrotestosterone (DHT) pellets in mice, which injected with noxious light/ dye 
stimulus to damage endothelium. They reported that androgen pellets increased platelet aggregation. 
However, when isolating platelets of those mice, platelets from mice treated with T, but not those treated 
with DHT, enhanced platelet reactivity. Thus, they concluded that the influence of T in increasing platelet 
aggregation was not a direct effect to platelets but indirectly through EC.   
Actually, T does have a direct influence to platelets as had been investigated by Matsuda et al. [16] 
in rats. They reported that rats treated with T cypionate for 2 weeks had an increased in platelets 
thromboxane receptor density and platelet aggregation. Ajayi & Haluskha [17] found that thromboxane 
receptor density in platelets from prostate cancer patients underwent surgically and/or medically castration is 
was significantly lower than controls.  
Campelo et al. [18] and Cutini et al. [19] offered another approach by incubating monolayer EC 
from rat aortic rings with PRP and T at various doses. After 1-minute incubation, PRP was removed from the 
plate and measured platelets aggregation by turbidimetric method using 5 µM of ADP as platelet agonist. 
They found that incubating PRP with monolayer EC decreased platelet aggregation as compared to PRP that 
was not exposed to EC. However, they showed that the presence of T depressed further platelet aggregation. 
What Campelo et al. [18] and Cutini et al. [19] had reported that T has anti-aggregatory action is contrary to 
what Rosenblum et al. [15], Matsuda et al. [16], and Ajayi and Haluskha [17] had proved that T has pro-
aggregatory action. The difference is the result of the design of the experiment. Campelo et al. [16] and 
Cutini et al. [19] applied T to EC and platelet at the same time, whereas Rosenblum et al. [15], Matsuda et al. 
[16], and Ajayi and Haluskha [17] were more focus to the exposure of T to platelet. Indeed, Khetawat et al. 
[20] showed that androgen receptors were detected in platelet. Differed with those previous experiments, in 
this study T does neither increase nor decrease platelet aggregation through EC.  
It has been established that diabetic environment promotes endothelial perturbation and dysfunction. 
HG condition in an in vitro study mimics hyperglycemia found in patients with DM [1]. There are numerous 
evidences for the role of EC as a break for platelet aggregation; however, only a few that reported the 
influence of HG condition to EC in relation to platelet activation. Cosentino et al. [21] had showed that the 
function of EC in preventing platelet aggregation is not optimal in HG medium because in this environment 
EC secrete prostanoid that functions as vasoconstrictor and pro platelet aggregation, i.e. thromboxane A2, 
much more than prostanoid that functions as vasodilator and antiplatelet aggregation, i.e. prostacyclin. It has 
been established also that T2DM patients have exaggerated platelet reactivity [22]-[23]. In agreement with 
literature, this study showed that HG environment increases platelet aggregation through EC.  
Shin et al. [24] and Cheung et al. [25] reported that serum T level was inversely correlated with 
plasma glucose level, whereas Hernadez-Mijares et al. [26] found that low T level was common among 
T2DM patients. It has been suggested that low T level is one of the consequences of DM. This study showed 
that HG does not interact with T in influencing platelet aggregation through EC. 
 
 
4. CONCLUSION  
Testosterone does not increase platelet aggregation through endothelial cells, but high glucose does. 
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